BRAF
EstablishedBRAF V600E drives multiple cancers via MAPK pathway activation, with opposite prognostic meaning in melanoma versus colorectal/thyroid cancer.
BRAF is a signaling protein, and one specific mutation in it drives several different cancers. Interestingly, this same mutation is good news in melanoma (since a very effective targeted drug combination exists) but is linked to worse outcomes in colon and thyroid cancer — the same mutation, opposite meaning, depending on where the cancer started.
BRAF is a kinase in the MAPK/ERK signaling pathway; the V600E mutation (over half of all BRAF mutations) constitutively activates this pathway, driving uncontrolled cell growth across several cancer types.
BRAF V600E occurs in about 50% of melanomas and papillary/anaplastic thyroid carcinomas, roughly 10% of colorectal cancers, and effectively 100% of hairy cell leukemia — connecting directly to the ACP5/TRAP discussion elsewhere in this biomarker set, where TRAP staining was historically used for the same diagnosis BRAF testing now confirms molecularly.
Detected via PCR-based mutation testing, NGS panels, or immunohistochemistry (VE1 antibody clone) as a faster, cheaper screening alternative, though IHC criteria remain less standardized in colorectal cancer specifically than in melanoma or thyroid cancer.
BRAF/MEK inhibitor combinations (vemurafenib, dabrafenib, trametinib, encorafenib, binimetinib) are standard therapy for BRAF V600E-mutant melanoma with strong survival benefit; the same mutation carries opposite prognostic meaning by cancer type — favorable in melanoma with targeted therapy available, but associated with poor prognosis and treatment resistance in colorectal and thyroid cancer.
Effectively universal in hairy cell leukemia, connecting to the historical TRAP/ACP5 diagnostic marker discussed elsewhere in this set.
- PMC. (2025). BRAF V600E liquid biopsy-based detection in precision oncology.
- European Thyroid Journal. (2025). BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.